Summary
Gilead Sciences, Inc. (GILD) reported robust financial results for the third quarter of 2014, driven significantly by the strong performance of its antiviral products, particularly Sovaldi. Total revenues surged to $6.04 billion, a substantial increase from $2.78 billion in the prior year's quarter. This growth was primarily fueled by Sovaldi sales, which reached $2.80 billion, and continued strength in their HIV single tablet regimens like Stribild and Complera/Eviplera. Despite increased Research and Development (R&D) and Selling, General & Administrative (SG&A) expenses, partly due to a one-time catch-up charge for the Branded Prescription Drug Fee, net income attributable to Gilead rose to $2.73 billion, or $1.67 per diluted share. The company also strengthened its balance sheet, ending the quarter with $7.69 billion in cash, cash equivalents, and marketable securities. Gilead's pipeline advanced with the approval of Harvoni for Hepatitis C, further solidifying its market position. Investors should note the significant legal proceedings related to sofosbuvir patents and ongoing generic competition as key areas to monitor.
Financial Highlights
55 data points| Revenue | $6.04B |
| Cost of Revenue | $987.00M |
| Gross Profit | $4.98B |
| R&D Expenses | $630.00M |
| SG&A Expenses | $945.00M |
| Operating Expenses | $2.56B |
| Operating Income | $3.48B |
| Interest Expense | $104.00M |
| Net Income | $2.73B |
| EPS (Basic) | $1.80 |
| EPS (Diluted) | $1.67 |
| Shares Outstanding (Basic) | 1.51B |
| Shares Outstanding (Diluted) | 1.64B |
Key Highlights
- 1Total revenues increased by 120% year-over-year to $6.04 billion, driven by strong antiviral product sales.
- 2Sovaldi sales were $2.80 billion for the quarter, representing 50% of total antiviral product sales.
- 3Net income attributable to Gilead was $2.73 billion, or $1.67 per diluted share, a significant increase from $788.6 million ($0.47 per diluted share) in the prior year.
- 4Operating cash flow for the first nine months of 2014 was $9.80 billion, a substantial increase from $2.38 billion in the same period of 2013.
- 5The company ended the quarter with $7.69 billion in cash, cash equivalents, and marketable securities, up from $2.57 billion at the end of 2013.
- 6Harvoni, a new Hepatitis C treatment, received U.S. FDA approval in October 2014, further enhancing Gilead's antiviral portfolio.
- 7Significant legal proceedings are ongoing, particularly related to sofosbuvir patents, with potential implications for future revenues and expenses.